Evidence map›Paper›PMID 29985736›Full record

ArticleHuman vaccines & immunotherapeutics2018

Immunotherapy of systemic sclerosis.

Christina G Katsiari, Theodora Simopoulou, Ioannis Alexiou, Lazaros I Sakkas

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Human vaccines & immunotherapeutics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. CAR-T cells in systemic sclerosis.Clinical rheumatology · 2026
    Review
  3. Stem cell therapy in systemic sclerosis.Clinical rheumatology · 2025
    Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Observational
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Christina G Katsiaria Department of Rheumatology and clinical Immunology, Faculty of Medicine, School of Health Sciences , University of Thessaly , Larissa , Greece.
Theodora Simopouloua Department of Rheumatology and clinical Immunology, Faculty of Medicine, School of Health Sciences , University of Thessaly , Larissa , Greece.
Ioannis Alexioua Department of Rheumatology and clinical Immunology, Faculty of Medicine, School of Health Sciences , University of Thessaly , Larissa , Greece.
Lazaros I Sakkasa Department of Rheumatology and clinical Immunology, Faculty of Medicine, School of Health Sciences , University of Thessaly , Larissa , Greece.
University of Thessaly · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Systemic sclerosis (SSc) is a chronic systemic disease characterized by microvasculopathy, immune activation, and extensive collagen deposition. Microvasculopathy and immune activation occur very early in the disease process. Evidence from animal models and in vitro studies indicate that T-cells and B-cells activate fibroblasts to produce collagen. Traditional immunosuppressants, cyclophosphamide(CyP), methotrexate(MTX), and more recently mycophenolate mofetil(MMF), may prove more effective if used very early in the disease course. These drugs showed some benefit in skin (MTX, CyP, MMF) and lung function (CyP, MMF). Biologicals, such as intravenous immunoglobulin (IVIg), belimumab(Beli), tocilizumab(TCZ), abatacept(Aba), rituximab(RTX) and fresolimumab(Fresu) appear promising as they exhibited some benefit in skin (IVIg, Beli, TCZ, Aba, RTX, Fresu), hand function (IVIg), and joints (IVIg, TCZ, Aba). Autologous stem cell transplantation showed the best therapeutic efficacy on skin and internal organs, and looks very promising, as modification of transplantation immunosuppression is decreasing the early high mortality.

Indexed as

abataceptautologous stem cellsbelimumabcyclophosphamideimmunomodulationIntravenous immunoglobulinmethotrexatemycophenolate mofetiltocilizumabtransplantation

Identifiers

PMID29985736
PMCPMC6314429
OpenAlexW2865200915

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.